利妥昔单抗生物类似药 (辉瑞制药)(Rituximab-Pvvr) - 药物靶点：CD20_在研适应症：CD20阳性弥漫性大B细胞淋巴瘤，霍奇金淋巴瘤，低级别 B 细胞非霍奇金淋巴瘤_专利_临床

概要

基本信息

药物类型

生物类似药、单克隆抗体

别名

Rituximab biosimilar、Rituximab biosimilar (Pfizer)、Rituximab-pvvr

+ [4]

靶点

CD20

作用机制

CD20抑制剂(B淋巴细胞抗原CD20抑制剂)、ADCC(抗体依赖的细胞毒作用)、CD20定向的溶细胞作用

治疗领域

肿瘤免疫系统疾病神经系统疾病+ [5]

在研适应症

CD20阳性弥漫性大B细胞淋巴瘤霍奇金淋巴瘤低级别 B 细胞非霍奇金淋巴瘤+ [14]

非在研适应症

CD20阳性滤泡性淋巴瘤

原研机构

Pfizer Inc.

在研机构

Pfizer Europe MA EEIG

Pfizer Australia Pty Ltd.

Pfizer Japan, Inc.

+ [1]

非在研机构

Pfizer Canada ULC

最高研发阶段批准上市

首次获批日期

美国 (2019-07-23),

CD20阳性B细胞慢性淋巴细胞白血病肉芽肿伴多血管炎显微镜下多血管炎+ [1]

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

序列信息

Sequence Code 27145L

当前序列信息引自: *****

Sequence Code 83181H

当前序列信息引自: *****

关联

2

项与利妥昔单抗生物类似药 (辉瑞制药) 相关的临床试验

NCT02213263 / Completed临床3期

A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF PF-05280586 VERSUS RITUXIMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH CD20-POSITIVE, LOW TUMOR BURDEN, FOLLICULAR LYMPHOMA

This study will compare the safety and effectiveness of PF-05280586 versus rituximab-EU in patients with CD20-positive, low tumor burden follicular lymphoma. The primary hypothesis to be tested in this study is that the effectiveness of PF-05280586, as measured by the Overall Response Rate, is similar to that of rituximab-EU.

开始日期2014-09-30

申办/合作机构

Pfizer Inc.

NCT01526057 / Completed临床2期

A RANDOMIZED, DOUBLE-BLIND, STUDY COMPARING THE PHARMACOKINETICS AND PHARMACODYNAMICS, AND ASSESSING THE SAFETY OF PF-05280586 AND RITUXIMAB IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS ON A BACKGROUND OF METHOTREXATE WHO HAVE HAD AN INADEQUATE RESPONSE TO ONE OR MORE TNF ANTAGONIST THERAPIES

In this study, patients with moderate to severe rheumatoid arthritis who are being treated with methotrexate will receive 2 intravenous treatments with either PF-05280586 or Rituxan (Rituximab) or MabThera (Rituximab). During the course of the study, the effects of the drugs will be assessed by sampling the levels of drug in the blood, blood cell counts, and by comparing these levels among the different treatments. Safety, tolerability and immunologic response also will be evaluated throughout.

开始日期2012-03-20

申办/合作机构

Pfizer Inc.

100 项与利妥昔单抗生物类似药 (辉瑞制药) 相关的临床结果

登录后查看更多信息

100 项与利妥昔单抗生物类似药 (辉瑞制药) 相关的转化医学

登录后查看更多信息

100 项与利妥昔单抗生物类似药 (辉瑞制药) 相关的专利（医药）

登录后查看更多信息

15

项与利妥昔单抗生物类似药 (辉瑞制药) 相关的文献（医药）

2024-07-02·EXPERT OPINION ON BIOLOGICAL THERAPY

Industry perspective on regulatory authority (RA) quality reviews of biosimilar applications – an evaluation of RA guidance and expectations for chemical, manufacturing, and controls information through in-depth query analysis

Article

作者: Tennyson, Scott D ; Hufnagel, Heather Rae

PURPOSE:

Evaluate the type and quantity of quality information (i.e. Chemistry, Manufacturing, and Control) requested by the US FDA and EMA in queries pertaining to biosimilar applications.

METHODS:

Numbers/types of queries received following regulatory submissions (FDA/EMA, n = 7/n = 5) for seven biosimilars (PF-filgrastim [Nivestym], PF-rituximab [Ruxience®], PF-trastuzumab [Trazimera®], PF-bevacizumab [Zirabev®], PF-pegfilgrastim [Nyvepria®], PF-adalimumab [Abrilada™/Amsparity®], PF-infliximab [Ixifi]) from a single product portfolio were analyzed considering published regulatory authority (RA) guidance and in relation to sections/subsections of Module 3: Quality from the Common Technical Document regulatory dossier and topics based on keyword assignment.

RESULTS:

Queries were most frequently assigned (FDA/EMA %, range) to Drug Substance Manufacture (subsection 3.2.S.2; 21-35%/13-50%), Control of Drug Substance (3.2.S.4; 3-11%/5-17%), Drug Product Pharmaceutical Development (3.2.P.2; 1-12%/1-15%) and Manufacture (3.2.P.3; 17-41%/2-13%), and Analytical Similarity (3.2.R; 4-21%/4-20%). The proportion of Drug Substance and Drug Product queries was significantly different between RAs (n1 = 952, n2 = 468, p-value <0.001; two-sample proportion z-test). Topic assignments included: Control (12-27%/12-28%), Manufacturing (56-72%/34-66%), Stability (1-12%/2-24%), Biosimilarity (5-16%/5-25%), and Container Closure (0-3%/0-9%).

CONCLUSION:

The focus of both RAs on topics related to manufacturing and controls is valuable in understanding expectations for scientific and technical content related to gaining biosimilar approval.

2023-11-21·Cureus

Effectiveness of Rituximab and Its Biosimilar in Treating Adult Steroid-Dependent Minimal Change Disease and Relapse

作者: Shan, Hui Yi

Minimal change disease (MCD) is an important cause of nephrotic syndrome in adults. Its course is often complicated by frequent relapses and steroid dependence. Most of the treatment experience of MCD comes from management of pediatric patients rather than adult patients. In this report, the author describes successful experience of using rituximab (RTX) and its biosimilar, RTX-pvvr (ruxience), to treat steroid-dependent MCD and relapses in adult patients. This is the first report of using a RTX biosimilar to treat MCD. This case series demonstrates that RTX and ruxience are well-tolerated, efficacious treatment for managing adult patients with steroid-dependent MCD and relapses.

2022-06-01·Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Rituximab-pvvr is not an independent predictor for infusion reactions in a cohort given rituximab-pvvr or rituximab: A single-center retrospective study

Letter

作者: Seabury, Robert ; Miller, Christopher ; Field, Allison ; Burgdorf, Andrew ; Triesel, Katherine

Our institution recently transitioned to rituximab-pvvr, a biosimilar of rituximab.Nursing staff anecdotally reported an increase in infusion reactions since this transition.We, therefore, sought to assess potential predictors for infusion reactions following rituximab-pvvr or rituximab administration.This retrospective chart review was performed at a single academic medical center with an affiliated outpatient cancer center.Patients given at least one dose of rituximab-pvvr or rituximab over a one-year period were identified through an electronic medical record query.In total, 490 patients were included in this anal., of which 55 had a documented infusion reaction and 435 did not.Rituximab was administered in 168 patients, and the other 322 patients received rituximab-pvvr.Rasburicase administration for tumor lysis syndrome prophylaxis and administration after chemotherapy were the only significant predictors on univariable anal.Chronic cardiac and pulmonary disease, heavy disease burden, rasburicase prophylaxis for tumor lysis, allopurinol prophylaxis for tumor lysis, administration after chemotherapy and rituximab-pvvr administration had p-values ≤ 0.25 on uni-variable anal. and were included in the logistic regression.Rasburicase prophylaxis for tumor lysis was the only significant predictor for rituximab-pvvr or rituximab infusions reactions on logistic regression.Rituximab-pvvr administration was not a significant predictor for infusion reactions on univariable anal. or logistic regression and the frequency of infusion reactions were not statistically different following rituximab-pvvr or rituximab administration (rituximab-pvvr: 12.4% (40/ 322) vs. rituximab: 8.9% (15/168), p = 0.245).In our study, rituximab-pvvr was not an independent predictor for infusion reactions and infusion reactions occurred at similar rates with rituximab-pvvr and rituximab.We, however, felt it was important to share our findings in case other institutions have similar perception, as it could limit rituximab-pvvr adoption and effect administration practices.

28

项与利妥昔单抗生物类似药 (辉瑞制药) 相关的新闻（医药）

2024-11-16

·PipelineReview

Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE1831 in IgG4-Related Disease

ALAMEDA, CA, USA and TAIPEI, Taiwan I November 15, 2024 I Acepodia (6976:TT), a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) and allogeneic gamma delta 2 (γδ2) T cell platforms, announced today that it has received U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application for the company’s lead candidate ACE 1831 in IgG4-related disease (IgG4-RD), a multi-organ, fibro-inflammatory autoimmune condition. This IND clearance allows Acepodia to investigate the safety and efficacy of Acepodia’s ACE1831 in patients with IgG4-RD, as its first step in autoimmune disease. ACE1831 utilizes bioorthogonal chemistry to link CD20-targeting antibodies to gamma delta T cells, creating an off-the-shelf, non-genetically engineered version of T cell therapy that is more easily scaled and may potentially mitigate side effects associated with autologous CAR-T cell therapies, such as T cell malignancies. ACE1831 is also in a Phase 1 dose escalation study for non-Hodgkin’s lymphoma (NHL). “Based on the observation of clinical benefits of CAR-T in autoimmune diseases, we hope to prove that ACE1831 can deliver ‘deeper’ B cell depletion than antibody drugs, critical for longer remission in autoimmune diseases,” said Sonny Hsiao, PhD, Chief Executive Officer, President and Co-Founder of Acepodia. “We’ve engaged accomplished IgG4-RD research physicians worldwide, excited by our innovative approach. This clearance enables us to launch the study, offering participants a promising new treatment,” commented Jerry Liu, MD, Head of Clinical Development of Acepodia. The Phase 1b/2a study of ACE1831 will be executed in collaboration with Pfizer Ignite, a service that offers biotech companies access to Pfizer’s significant resources, scale, and expertise to accelerate the progression of potential breakthrough medicines for patients. The study will be led by Dr. John Stone, MD, MPH, of Massachusetts General Hospital, Executive Chairman of The IgG4ward! Foundation and an eminent IgG4-RD researcher whose work identified the potential of targeted B-cell depletion with rituximab. Dr. Stone said, “A crucial finding for people living with IgG4-RD now has been the efficacy in disease control exerted by B cell depletion. I’m enthusiastic now not only about the possibility of deeper B cell depletion with Acepodia’s approach, but also about its ease of use and potential for fewer adverse effects than other cell-based approaches.” About Acepodia Acepodia is a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) platform technology to address gaps in cancer care. Leveraging its ACC technology, the company links tumor-targeting antibodies to its proprietary immune cells, such as natural killer and gamma delta T cells, to create novel ACE therapies, which have increased binding strength against tumors that express low levels of tumor antigens as well as pathogenic B cells causing autoimmune disease. Acepodia is composed of seasoned leaders and scientific experts dedicated to advancing its robust pipeline of ACE therapies with the potential to bring innovative, effective, and affordable cell therapies to a broad population of patients across a variety of solid tumors and hematologic cancers. For more information, visit www.acepodia.com and follow Acepodia on Twitter and LinkedIn . SOURCE: Acepodia

细胞疗法临床申请免疫疗法临床1期

2024-11-15

·PRNewswire

Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE1831 in IgG4-Related Disease

IND clearance paves the way for Acepodia to enter the clinic for the first time with its autoimmune program ACE1831 is an allogeneic gamma delta T cell therapy candidate targeting CD20-expressing cells currently being investigated in non-Hodgkin's lymphoma (NHL) The planned clinical study will be executed as part of strategic clinical collaboration with Pfizer Ignite ALAMEDA, Calif. and TAIPEI, Nov. 15, 2024 /PRNewswire/ -- Acepodia (6976:TT), a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) and allogeneic gamma delta 2 (γδ2) T cell platforms, announced today that it has received U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application for the company's lead candidate ACE 1831 in IgG4-related disease (IgG4-RD), a multi-organ, fibro-inflammatory autoimmune condition. This IND clearance allows Acepodia to investigate the safety and efficacy of Acepodia's ACE1831 in patients with IgG4-RD, as its first step in autoimmune disease. ACE1831 utilizes bioorthogonal chemistry to link CD20-targeting antibodies to gamma delta T cells, creating an off-the-shelf, non-genetically engineered version of T cell therapy that is more easily scaled and may potentially mitigate side effects associated with autologous CAR-T cell therapies, such as T cell malignancies. ACE1831 is also in a Phase 1 dose escalation study for non-Hodgkin's lymphoma (NHL). "Based on the observation of clinical benefits of CAR-T in autoimmune diseases, we hope to prove that ACE1831 can deliver 'deeper' B cell depletion than antibody drugs, critical for longer remission in autoimmune diseases," said Sonny Hsiao, PhD, Chief Executive Officer, President and Co-Founder of Acepodia. "We've engaged accomplished IgG4-RD research physicians worldwide, excited by our innovative approach. This clearance enables us to launch the study, offering participants a promising new treatment," commented Jerry Liu, MD, Head of Clinical Development of Acepodia. The Phase 1b/2a study of ACE1831 will be executed in collaboration with Pfizer Ignite, a service that offers biotech companies access to Pfizer's significant resources, scale, and expertise to accelerate the progression of potential breakthrough medicines for patients. The study will be led by Dr. John Stone, MD, MPH, of Massachusetts General Hospital, Executive Chairman of The IgG4ward! Foundation and an eminent IgG4-RD researcher whose work identified the potential of targeted B-cell depletion with rituximab. Dr. Stone said, "A crucial finding for people living with IgG4-RD now has been the efficacy in disease control exerted by B cell depletion. I'm enthusiastic now not only about the possibility of deeper B cell depletion with Acepodia's approach, but also about its ease of use and potential for fewer adverse effects than other cell-based approaches." About Acepodia Acepodia is a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) platform technology to address gaps in cancer care. Leveraging its ACC technology, the company links tumor-targeting antibodies to its proprietary immune cells, such as natural killer and gamma delta T cells, to create novel ACE therapies, which have increased binding strength against tumors that express low levels of tumor antigens as well as pathogenic B cells causing autoimmune disease. Acepodia is composed of seasoned leaders and scientific experts dedicated to advancing its robust pipeline of ACE therapies with the potential to bring innovative, effective, and affordable cell therapies to a broad population of patients across a variety of solid tumors and hematologic cancers. For more information, visit and follow Acepodia on Twitter and LinkedIn. SOURCE Acepodia Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

细胞疗法临床申请免疫疗法临床1期

2024-08-21

·空之客

【医苑观畴】2024年二季度海外药企进展更新：辉瑞PFE

1 整体表现曾经的宇宙第一大厂辉瑞，在新冠口服药和疫苗的潮水迅速退去的过程中，仿佛又回到了业绩增长点全线哑火的尴尬境地，于是市值从22年最风光时短暂达到过的$300b、近期又回到了$150b左右，在大药企的市值排名一下落到第9名（顺便吐个槽，自从疫情结束后，PFE看点急剧衰竭的程度从季报篇幅的缩水就可见一斑，这家顶级MNC的季报如果不算封面封底脚注居然只有10页纸……）扣除新冠产品以外的收入同比增长14%，但其实其中也有一大半的增量又是来源于合并SGEN那些ADC产品，所以实际上可比的内生增长依然非常微不足道，而且净利润也在下降。 2 已上市产品肿瘤板块的业绩只能说是小打小闹，最粗的大腿Palbociclib早已日薄西山，Enzalutamide看起来在联用PARP抑制剂获批之后确实对销售额颇有贡献、LTM累计已达到$1.5b，BRAF+MEK组合这个季度也有所起色、单季$150m，不过$43b重金买来的SGEN单季度只贡献了区区$827m、爬坡也算不上明显、不知道距离2030年贡献超过$10b这个目标还有多远。免疫炎症板块更是惨不忍睹，老迈不堪的Tofacitinib和Etanercept正在一路下滑，而新一代JAK抑制剂Abrocitinib上市两年多LTM累计才$163m，与单季度都已经$1.4b的Upadacitinib一比简直高下立判。传染病板块里，除去新冠两兄弟的一地鸡毛，也就靠LTM累计$6.5b的肺炎疫苗Prevnar独撑危局了，新上市的RSV疫苗Abrysvo首个年度打破$1b大关也算给未来留下看点。其他产品倒是看点颇多：Apixaban还算是老骥伏枥，加上BMS部分LTM累计已接近$20b大关；TTR稳定剂Tafamidis划出一条完美的成长曲线，LTM累计已高达$4.3b，尽管面对后续ALNY和BBIO的潜在冲击，至少已经证明ATTR-CM/PN的确是有巨大潜力的适应症（参见【药海听涛】太阳神终于降临：Alnylam公布HELIOS-B三期结果）；偏头痛药物Rimegepant也改出了此前几个季度走平的状态，LTM累计突破$1.0b，至少作为同适应症药物已经超越了LLY的Galcanezumab、ABBV的Atogepant和Ubrogepant、NVS的Erenumab，成为偏头痛和CGRP中市场份额的领跑者。 3 在研管线这个季度PFE最吸睛的消息就是小分子GLP-1的“借尸还魂”，在此前终止了Danuglipron每日两次剂型的开发后，每日一次控释剂型的优化完成并准备启动桥接试验。基因治疗好像久远得像上古时代的产物，PFE曾经在这里砸下的重金也总算听到点儿回响，治疗A型血友病的AAV项目SB-525读出了三期临床的topline数据，从输注后第12周到至少15个月的随访期间，单次3e13 vg/kg SB-525与八因子替代预防疗法相比，平均总年化出血率（ABR）为1.24 vs 4.73（p=0.0040）；然而另一个治疗DMD的AAV项目却遭遇三期临床失败。除此以外，值得关注的进展还包括：Adcetris公布了联用Lenalidomide和Rituximab治疗DLBCL的三期临床数据并提交sBLA，长效生长激素Somatrogon向欧洲药监部门提交上市申请，RSV疫苗Abrysvo公布了免疫低下成年人群的三期临床数据、并获批Act-O-Vial剂型，BCMA/CD3双抗Elranatamab公布二期临床中1L MM亚组的OS数据，。说得不客气点，PFE就像一具被新冠业务吸干了精气的僵尸，庞大的身躯虽然仍有动作，却表现出令人费解的茫然混沌，早已失去了曾经作为宇宙第一大药企的方向感和驱动力。从他其实早早发了季报，我直到现在才愿意细看一眼（然而并没看到什么值得期待的内容），就知道期望值有多低……

疫苗临床3期基因疗法财报引进/卖出

100 项与利妥昔单抗生物类似药 (辉瑞制药) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	利妥昔单抗生物类似药 (辉瑞制药)	L01XC02	DB00073

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
CD20阳性弥漫性大B细胞淋巴瘤	欧盟	Pfizer Europe MA EEIG	2023-12-15
CD20阳性弥漫性大B细胞淋巴瘤	冰岛	Pfizer Europe MA EEIG	2023-12-15
CD20阳性弥漫性大B细胞淋巴瘤	列支敦士登	Pfizer Europe MA EEIG	2023-12-15
CD20阳性弥漫性大B细胞淋巴瘤	挪威	Pfizer Europe MA EEIG	2023-12-15
霍奇金淋巴瘤	欧盟	Pfizer Europe MA EEIG	2023-12-15
霍奇金淋巴瘤	冰岛	Pfizer Europe MA EEIG	2023-12-15
霍奇金淋巴瘤	列支敦士登	Pfizer Europe MA EEIG	2023-12-15
霍奇金淋巴瘤	挪威	Pfizer Europe MA EEIG	2023-12-15
低级别 B 细胞非霍奇金淋巴瘤	澳大利亚	Pfizer Australia Pty Ltd.	2021-03-03
获得性血栓性血小板减少性紫癜	日本	Pfizer Japan, Inc.	2020-11-18
慢性特发性血小板减少性紫癜	日本	Pfizer Japan, Inc.	2020-08-05
CD20阳性的B细胞非霍奇金淋巴瘤	欧盟	Pfizer Europe MA EEIG	2020-04-01
CD20阳性的B细胞非霍奇金淋巴瘤	冰岛	Pfizer Europe MA EEIG	2020-04-01
CD20阳性的B细胞非霍奇金淋巴瘤	列支敦士登	Pfizer Europe MA EEIG	2020-04-01
CD20阳性的B细胞非霍奇金淋巴瘤	挪威	Pfizer Europe MA EEIG	2020-04-01
难治性慢性淋巴细胞白血病	欧盟	Pfizer Europe MA EEIG	2020-04-01
难治性慢性淋巴细胞白血病	冰岛	Pfizer Europe MA EEIG	2020-04-01
难治性慢性淋巴细胞白血病	列支敦士登	Pfizer Europe MA EEIG	2020-04-01
难治性慢性淋巴细胞白血病	挪威	Pfizer Europe MA EEIG	2020-04-01
慢性淋巴细胞白血病	欧盟	Pfizer Europe MA EEIG	2020-04-01

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
CD20阳性滤泡性淋巴瘤	临床3期	美国	Pfizer Inc.	2014-09-30
CD20阳性滤泡性淋巴瘤	临床3期	日本	Pfizer Inc.	2014-09-30
CD20阳性滤泡性淋巴瘤	临床3期	奥地利	Pfizer Inc.	2014-09-30
CD20阳性滤泡性淋巴瘤	临床3期	白俄罗斯	Pfizer Inc.	2014-09-30
CD20阳性滤泡性淋巴瘤	临床3期	比利时	Pfizer Inc.	2014-09-30
CD20阳性滤泡性淋巴瘤	临床3期	巴西	Pfizer Inc.	2014-09-30
CD20阳性滤泡性淋巴瘤	临床3期	克罗地亚	Pfizer Inc.	2014-09-30
CD20阳性滤泡性淋巴瘤	临床3期	法国	Pfizer Inc.	2014-09-30
CD20阳性滤泡性淋巴瘤	临床3期	格鲁吉亚	Pfizer Inc.	2014-09-30
CD20阳性滤泡性淋巴瘤	临床3期	德国	Pfizer Inc.	2014-09-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02213263 (Not provided \| REFLECTIONS, Pubmed \| BioDrugs)	临床3期	CD20阳性滤泡性淋巴瘤	394	PF-05280586	艱築夢廠製願鹹遞網壓(願觸窪願艱範鹹選簾鬱) = 餘蓋襯鏇鏇鏇簾遞範選餘蓋願蓋製顧構鬱繭網 (鏇餘壓蓋製網窪淵憲壓 ) 更多	-	2020-04-01
				Rituximab Reference Product (MabThera®)	艱築夢廠製願鹹遞網壓(願觸窪願艱範鹹選簾鬱) = 築鬱選構壓簾網鹽蓋齋餘蓋願蓋製顧構鬱繭網 (鏇餘壓蓋製網窪淵憲壓 ) 更多
NCT01526057 (REFLECTIONS, CTgov)	临床2期	类风湿关节炎	220	Rituximab (Rituximab-Pfizer)	餘鹽繭齋蓋蓋淵廠醖構(構觸積膚醖顧遞襯餘網) = 鑰範憲簾觸襯製鬱選衊鬱獵觸憲餘膚衊窪觸蓋 (選網蓋艱艱遞鹽願鑰艱, 獵願膚艱繭壓壓簾願願 ~ 夢衊積網鬱簾顧鏇蓋顧) 更多	-	2019-11-19
				Rituximab (Rituximab-EU)	餘鹽繭齋蓋蓋淵廠醖構(構觸積膚醖顧遞襯餘網) = 鹽襯廠襯艱鬱衊餘鹹鏇鬱獵觸憲餘膚衊窪觸蓋 (選網蓋艱艱遞鹽願鑰艱, 鬱蓋構簾鑰窪蓋鏇範網 ~ 顧獵淵鏇壓艱醖築鹹憲) 更多
NCT02213263 (REFLECTIONS, ASH2018) 人工标引	临床3期	CD20阳性滤泡性淋巴瘤一线 CD20 Positive	394	PF-05280586	鬱鹹積獵夢觸選艱膚遞(鹹壓窪膚鹽顧壓餘襯觸) = 襯繭鑰顧範顧齋壓膚觸製齋醖艱憲壓膚製憲願 (蓋積願淵鏇醖醖網築積 ) 更多	相似	2018-11-29
				Rituximab-EU	鬱鹹積獵夢觸選艱膚遞(鹹壓窪膚鹽顧壓餘襯觸) = 糧觸觸醖窪廠築繭鑰製製齋醖艱憲壓膚製憲願 (蓋積願淵鏇醖醖網築積 ) 更多
NCT02213263 (Not provided \| REFLECTIONS, CTgov)	临床3期	CD20阳性滤泡性淋巴瘤	394	PF-05280586	製顧簾衊糧簾衊衊鏇鏇(齋繭築獵選獵範鏇醖齋) = 獵積壓糧製齋積憲構醖選選築淵築積糧壓觸襯 (製壓蓋獵壓範鏇蓋糧繭, 選憲鏇齋壓觸鏇觸獵蓋 ~ 壓蓋願積鹽蓋餘顧願鬱) 更多	-	2018-10-30